A 37-year-old volunteer in Oxford, UK, has received the first dose of an experimental vaccine against the Bundibugyo strain of the Ebola virus, marking the start of human clinical evaluation for a pathogen that has, until now, lacked any approved vaccine or treatment. The ChAdOx1 BDBV candidate, designed by Oxford University’s Pandemic Sciences Institute and manufactured by the Serum Institute of India, moved from concept to clinic in just eight weeks—a timeline enabled by the adenoviral vector platform that underpinned the Oxford/AstraZeneca Covid-19 vaccine. The Coalition for Epidemic Preparedness Innovations (CEPI) is funding the $8.6 million programme, and 620,000 doses have already been stockpiled in anticipation of potential emergency use.

The trial is a Phase I, dose-escalation study that will assess safety and immunogenicity in healthy adults; the sample size has not been disclosed. Its launch coincides with a rapidly deteriorating epidemiological situation in the Democratic Republic of Congo (DRC), where the current Bundibugyo outbreak has been designated a Public Health Emergency of International Concern by the World Health Organization. After harmonising national and provincial data, health authorities in Kinshasa now report 2,905 confirmed cases and 1,269 deaths as of 22 July, making this the fastest-spreading Ebola outbreak ever recorded. It reached 1,000 fatalities in just over two months, nearly three times faster than the 2014–2016 West African epidemic.

The epicentre lies in the conflict-ravaged provinces of Ituri and North Kivu, where insecurity, mass displacement, and community mistrust complicate contact tracing and the isolation of patients. Almost 90% of cases are concentrated in these eastern areas, though imported infections have appeared in Uganda. The Bundibugyo virus is distinct from the more common Zaire ebolavirus: it has no proven medical countermeasures, and the current case fatality rate of around 40% reflects both late presentation and gaps in the surveillance system. Officials in Goma and Geneva caution that the true peak may still lie ahead, given that the index case remains unidentified and a significant share of new infections occur outside monitored contact chains.

Viewed from Oxford and Pune, the trial’s rapid initiation signals a new level of preparedness, but the path to a licensed product is long. Initial data on antibody responses and reactogenicity are expected in the coming months; even under accelerated regulatory pathways, an approved vaccine is unlikely to be available before late 2027. In parallel, teams on the ground continue to rely on isolation, safe burials, and community engagement to break transmission chains.